Terms: = Brain cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169
200 results:
1. PROTAC ezh2 degrader-1 overcomes the resistance of podophyllotoxin derivatives in refractory small cell lung cancer with leptomeningeal metastasis.
Shi MX; Ding X; Tang L; Cao WJ; Su B; Zhang J
BMC Cancer; 2024 Apr; 24(1):504. PubMed ID: 38644473
[TBL] [Abstract] [Full Text] [Related]
2. An epigenetic barrier sets the timing of human neuronal maturation.
Ciceri G; Baggiolini A; Cho HS; Kshirsagar M; Benito-Kwiecinski S; Walsh RM; Aromolaran KA; Gonzalez-Hernandez AJ; Munguba H; Koo SY; Xu N; Sevilla KJ; Goldstein PA; Levitz J; Leslie CS; Koche RP; Studer L
Nature; 2024 Feb; 626(8000):881-890. PubMed ID: 38297124
[TBL] [Abstract] [Full Text] [Related]
3. PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo.
Brown EJ; Balaguer-Lluna L; Cribbs AP; Philpott M; Campo L; Browne M; Wong JF; Oppermann U; Carcaboso ÁM; Bullock AN; Farnie G
Sci Rep; 2024 Jan; 14(1):328. PubMed ID: 38172189
[TBL] [Abstract] [Full Text] [Related]
4. Ribosomal S6 protein kinase 4 promotes resistance to ezh2 inhibitors in glioblastoma.
Pang F; Zhang L; Li M; Yi X; Wang Y; Yang P; Wen B; Jiang J; Teng Y; Yang X; Chen L; Xu J; Wang L
Cancer Gene Ther; 2023 Dec; 30(12):1636-1648. PubMed ID: 37726387
[TBL] [Abstract] [Full Text] [Related]
5. Targeting ezh2 regulates the biological characteristics of glioma stem cells via the Notch1 pathway.
Zhao G; Deng Z; Li X; Wang H; Chen G; Feng M; Zhou Y
Exp Brain Res; 2023 Oct; 241(10):2409-2418. PubMed ID: 37644332
[TBL] [Abstract] [Full Text] [Related]
6. ezh2-regulated PARP-1 Expression is a Likely Mechanism for the Chemoresistance of Gliomas to Temozolomide.
Liang Q; Wang B; Zhang C; Song C; Wang J; Sun W; Jiang L; Lin J
Curr Cancer Drug Targets; 2024; 24(3):328-339. PubMed ID: 37594167
[TBL] [Abstract] [Full Text] [Related]
7. The Role of CDK20 Protein in Carcinogenesis.
Chivukula S; Malkhed V
Curr Drug Targets; 2023; 24(10):790-796. PubMed ID: 37469151
[TBL] [Abstract] [Full Text] [Related]
8. Identification of genomic biomarkers and their pathway crosstalks for deciphering mechanistic links in glioblastoma.
Quddusi DM; Bajcinca N
IET Syst Biol; 2023 Aug; 17(4):143-161. PubMed ID: 37277696
[TBL] [Abstract] [Full Text] [Related]
9. Circadian clock protein Bmal1 accelerates acute myeloid leukemia by inhibiting ferroptosis through the EBF3/ALOX15 axis.
Wang D; Wang F; Zhang H; Chen P; Yang M
Cancer Sci; 2023 Aug; 114(8):3446-3460. PubMed ID: 37271497
[TBL] [Abstract] [Full Text] [Related]
10. A genomic score to predict local control among patients with brain metastases managed with radiation.
Lamba N; Cagney DN; Catalano PJ; Kim D; Elhalawani H; Haas-Kogan DA; Wen PY; Wagle N; Aizer AA
Neuro Oncol; 2023 Oct; 25(10):1815-1827. PubMed ID: 37260393
[TBL] [Abstract] [Full Text] [Related]
11. Tazemetostat for tumors harboring SMARCB1/SMARCA4 or ezh2 alterations: results from NCI-COG pediatric MATCH APEC1621C.
Chi SN; Yi JS; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey BD; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Ramirez NC; Jaju A; Mhlanga JC; Fox E; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW
J Natl Cancer Inst; 2023 Nov; 115(11):1355-1363. PubMed ID: 37228094
[TBL] [Abstract] [Full Text] [Related]
12. ezh2-Myc driven glioblastoma elicited by cytomegalovirus infection of human astrocytes.
El Baba R; Pasquereau S; Haidar Ahmad S; Monnien F; Abad M; Bibeau F; Herbein G
Oncogene; 2023 Jun; 42(24):2031-2045. PubMed ID: 37147437
[TBL] [Abstract] [Full Text] [Related]
13. β-Catenin-Driven Differentiation Is a Tissue-Specific Epigenetic Vulnerability in Adrenal cancer.
Mohan DR; Borges KS; Finco I; LaPensee CR; Rege J; Solon AL; Little DW; Else T; Almeida MQ; Dang D; Haggerty-Skeans J; Apfelbaum AA; Vinco M; Wakamatsu A; Mariani BMP; Amorim LC; Latronico AC; Mendonca BB; Zerbini MCN; Lawlor ER; Ohi R; Auchus RJ; Rainey WE; Marie SKN; Giordano TJ; Venneti S; Fragoso MCBV; Breault DT; Lerario AM; Hammer GD
Cancer Res; 2023 Jul; 83(13):2123-2141. PubMed ID: 37129912
[TBL] [Abstract] [Full Text] [Related]
14. Targeting B7‑H3 through ezh2 inhibition in MYC‑positive Group 3 medulloblastoma.
Shishido K; Purvis IJ; Velpula KK; Venkataraman S; Vibhakar R; Asuthkar S
Oncol Rep; 2023 Jun; 49(6):. PubMed ID: 37114557
[TBL] [Abstract] [Full Text] [Related]
15. Downregulation of BASP1 Promotes Temozolomide Resistance in Gliomas via Epigenetic Activation of the FBXO32/NF-κB/MGMT Axis.
Liao X; Li Z; Zheng H; Qian W; Zhang S; Chen S; Li X; Tang M; Xu Y; Yu R; Li M; Song L; Li J
Mol Cancer Res; 2023 Jul; 21(7):648-663. PubMed ID: 36961398
[TBL] [Abstract] [Full Text] [Related]
16. Loss of p53 Concurrent with RAS and TERT Activation Induces Glioma Formation.
Gong M; Fan X; Yu H; Niu W; Sun S; Wang H; Chen X
Mol Neurobiol; 2023 Jun; 60(6):3452-3463. PubMed ID: 36867344
[TBL] [Abstract] [Full Text] [Related]
17. A neurodevelopmental epigenetic programme mediated by SMARCD3-DAB1-Reelin signalling is hijacked to promote medulloblastoma metastasis.
Zou H; Poore B; Brown EE; Qian J; Xie B; Asimakidou E; Razskazovskiy V; Ayrapetian D; Sharma V; Xia S; Liu F; Chen A; Guan Y; Li Z; Wanggou S; Saulnier O; Ly M; Fellows-Mayle W; Xi G; Tomita T; Resnick AC; Mack SC; Raabe EH; Eberhart CG; Sun D; Stronach BE; Agnihotri S; Kohanbash G; Lu S; Herrup K; Rich JN; Gittes GK; Broniscer A; Hu Z; Li X; Pollack IF; Friedlander RM; Hainer SJ; Taylor MD; Hu B
Nat Cell Biol; 2023 Mar; 25(3):493-507. PubMed ID: 36849558
[TBL] [Abstract] [Full Text] [Related]
18. The epigenetic ezh2/H3K27me3 axis modulates lactotroph tumor cell proliferation.
Zlocowski N; Sosa LDV; De la Cruz-Thea B; Guido CB; Martín MG; Mukdsi JH; Torres AI; Petiti JP
J Endocrinol; 2023 May; 257(2):. PubMed ID: 36786578
[TBL] [Abstract] [Full Text] [Related]
19. How I treat recurrent pediatric high-grade glioma (pHGG): a Europe-wide survey study.
Perwein T; Giese B; Nussbaumer G; von Bueren AO; van Buiren M; Benesch M; Kramm CM
J Neurooncol; 2023 Feb; 161(3):525-538. PubMed ID: 36720762
[TBL] [Abstract] [Full Text] [Related]
20. PRC2 disruption in cerebellar progenitors produces cerebellar hypoplasia and aberrant myoid differentiation without blocking medulloblastoma growth.
Cleveland AH; Malawsky D; Churiwal M; Rodriguez C; Reed F; Schniederjan M; Velazquez Vega JE; Davis I; Gershon TR
Acta Neuropathol Commun; 2023 Jan; 11(1):8. PubMed ID: 36635771
[TBL] [Abstract] [Full Text] [Related]
[Next]
